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Figure 7 
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FIGURE 8 
PURIFICATION SCHEME 
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FIGURE 9 
Western Blot (under non-reducing conditions) 
Sample 
hfib, 1 OO ngs 
TG 1-11-4 (pellet-2), 15 ngs 
TG 1-11-4 (pellet-2), 15 ngs 
TG 1-6-9 (pellet-2), 30 ngs 
TG 1-6-9 (pellet-2), 30 ngs 
Diafiltered mouse plasma, 1-2 Augs 
NTG (pellet-2), 600 ngs 
hfib, 1 O ngs 
n 8 
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FIGURE 10 
Western Blot (SDS-PAGE under Reducing Conditions) 
Lane Sample 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
human Fibrinogen (100 ngs) 
hFib (50 ngs) 
hFib (1 Ongs) 
Mouse Plasma Derivative (200 ngs) 
TG whey (pellet-2) 60 ngs 
TG whey (pellet-2) 30 ngs 
TG whey (pellet-2) 15 ngs 
TG whey (pellet-2) 8 ngs 
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FIGURE 11 
Analysis of products under reducing conditions 
Thrombin assisted clot formation 
L are Sample 
hFib (5O ngs)-before Thrombin 
hFib (1 O ngs)-before Thrombin 
hFib (10 ngs)-resuspended clot 
TG whey (pellet-2) 30 ngs-before Thrombin 
TG whey (pellet-2)-resuspended clot 
Mouse Plasma Derivative 1 OOO ngs-before Thrombin 
Mouse Plasma Derivative 1 OOO ngs-resuspended 
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TRANSGENIC NONHUMAN MAMMALS 
PRODUCING FIBRINOGEN IN MILKAND 
METHODS OF PRODUCING FIBRN 
Cross-Reference To Related Applications 
This application is a divisional of U.S. Ser. No. 08/443,184, 
filed on May 17, 1995, now U.S. Pat. No. 6,984,772, which is 
a continuation-in-part of U.S. Ser. No. 08/198,068, filed on 
Feb. 18, 1994, now abandoned, each of which are incorpo 
rated herein by reference in their entirety. 
BACKGROUND OF THE INVENTION 
The present invention relates in general to the use of trans 
genic animals to produce therapeutically useful amounts of 
clinically important recombinant proteins. More particularly, 
this invention relates to the production in transgenic animals 
of clinically useful quantities of the blood clotting protein, 
fibrinogen (“FIB’). 
The ultimate event in the blood clotting cascade is the 
thrombin-catalyzed conversion of FIB (Mr 340,000) to 
fibrin (Mr 329,000), the latter forming the fibrin clot. FIB 
deficiency is generally transmitted as an autosomal recessive 
trait and may manifest as a complete or partial absence of FIB 
from the blood plasma. Clinically, the disease resembles 
moderate or mild hemophilia. Congenital fibrinogen abnor 
mality may be due to the hereditary synthesis of structurally 
or functionally abnormal molecules, as in Vlissingen, 
Ijmuiden and Nijmegen fibrinogens. An acquired deficiency 
of this protein may occur due to impaired hepatic synthesis of 
the protein, as occurs, for example, in hepatitis or hepatic 
necrosis, or to accelerated destruction of the protein caused, 
for example, by increased blood proteolytic activity. 
Control of bleeding in such patients is currently achieved 
by transfusion of FIB contained in freshly-frozen human 
plasma or in concentrates of the protein isolated from donor 
blood. While these replacement therapies are generally effec 
tive, they place patients at risk for virus-transmissible dis 
eases such as hepatitis or AIDS. Although this risk has been 
greatly reduced by inactivating such viruses with heat or 
organic solvents, such preparations have greatly increased the 
cost of treatment, and are not risk free. There is thus a critical 
need for a source of this protein alternate to human plasma. 
An important advance in obtaining an alternate clinical 
source of FIB has been the cloning of cDNAs encoding the 
three different fibrinogen chains, and the publication of 
cDNA sequences. Rixon et al., Biochemistry 22:3237 (1983); 
Chung et al., ibid: 3244; Chung et al., ibid: 3250. The struc 
ture of the FIB molecule is exceedingly complex. Each mol 
ecule of FIB consists oftwo sets of three different polypeptide 
chains, designated AC, Bf3 and Gy, with molecular masses of 
66 kDa, 52 kDa and 46.5 kDa, respectively. The two half 
molecules containing each set of chains are linked together by 
three disulfide bonds. In addition, a complex set of intra- and 
inter-chain disulfide bonds (there are a total of 29 disulfide 
bonds with no free sulfhydryl groups) are involved in main 
taining proper functional structure. Further, FIB is a glyco 
protein with highly specific glycosylations. The molecule 
contains four carbohydrate chains, one each on the B. B. G 
and Y chains; the C. and A chains contain no carbohydrate. 
About 11 kDa of the total molecular mass of FIB (340kDa) is 
attributable to this carbohydrate, added to the molecule post 
translationally. In addition, isoforms of glycoproteins are 
known corresponding to differences in Sialic acids on the 
carbohydrate chains. Proper carbohydrate modification is 
required for functional activity of FIB. 
10 
15 
25 
30 
35 
40 
45 
50 
55 
60 
65 
2 
These highly complex characteristics of the functional FIB 
molecule has made unpredictable and difficult the expression, 
assembly and secretion of fully formed and functional recom 
binant molecules. A cDNA encoding the human FIBAC. 
chain has been expressed in bacteria. Lord, DNA 4:33 (1985). 
This is of limited usefulness, however, since the other fibrino 
gen chains that bear carbohydrates cannot be produced in 
prokaryotes. 
Individual FIB chains have been expressed in COS1 (trans 
formed monkey kidney fibroblast) cells. Danishevsky et al., 
Biochim. Biophys. Acta 1048: 202 (1990). In addition, trans 
fecting COS1 cells with a combination of cDNAs encoding 
the individual human fibrinogen subunit chains is reported to 
produce the holoprotein, but the amounts produced were 
Small, and Substantially less than the production achieved in 
the transgenic animal systems to be described below. Roy et 
al., J. Biol. Chem., 266: 4758 (1991). The secretion of par 
tially assembled or wholly unassembled and separate human 
FIB (“hFIB) or recombinant human FIB ("rhFIB) chains 
has not been reported for native or genetically engineered 
tissues. Chung et al. (1983); Danishevsky et al (1990). In 
addition, there are serious drawbacks to the use of mamma 
lian cell tissue culture systems for production of FIB. These 
include the high costs of growth media, the labor intensive 
nature of such systems, and limited production capacity. 
An important need persists for an efficient and relatively 
inexpensive means of producing clinically useful amounts of 
infectious particle-free rhFIB protein. The present invention 
satisfies this need. It has been Surprisingly found that trans 
genic animals can be genetically engineered to produce and 
secrete into readily accessible body fluids therapeutically 
useful quantities of rhFIB. In addition to therapeutic uses 
involving replacement or addition therapy, the FIB of the 
invention finds us in a variety of applications, such as a “glue' 
in Surgical procedures, as a delivery system for drugs, such as 
antibiotics or anti-parasitic agents, to wounds, as a food Sub 
stitute, and for altering the composition of milk. These trans 
genic systems are described below. 
SUMMARY OF THE INVENTION 
In accordance with the present invention, there is provided 
a non-human mammalian animal that has stably integrated 
into its genome heterologous (that is, exogenously derived) 
polynucleotides that encode the AC, BB and GY polypeptide 
chains of human FIB, and that direct by means of regulatory 
and signal sequences the expression of biologically active 
rhFIB in mammary gland cells, such that newly synthesized 
fibrinogen is secreted into bodily fluid compartments, par 
ticularly milk, blood or urine of the animal. By integrating 
fewer than all of the three heterologous polynucleotides, indi 
vidual chains of fibrinogen can be produced and may be 
secreted. By integrating heterologous polynucleotides that 
have been modified prior to administration to the host animal, 
modified FIB and products thereof can be produced. 
It therefore is an object of the present invention to provide 
transgenic animals capable of producing rhFIB, individual 
polypeptide subunit chains of FIB, or FIB-derived proteins 
and protein products. 
It is also an object of the invention to provide a means of 
producing rhFIB, individual polypeptide subunits thereof, or 
FIB-derived proteins and protein products in transgenic ani 
mals. 
In a preferred embodiment of this aspect of the invention, 
lactating transgenic animals produce the rhFIB, individual 
FIB subunits or FIB-derived proteins in their mammary 
glands and secrete these products in their milk. In another 
US 7,435,869 B2 
3 
preferred embodiment, transgenic animals secrete the pro 
duced rhFIB, individual FIB subunits, or FIB-derived pro 
teins in their blood and/or urine. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a sketch of the murine WAP gene. 
FIG. 2 is a sketch of the plasmid puCWAP4 cassette vector 
containing -2.6 kbp of WAP 5" promotor region, ~1.3 kbp of 
WAP 3' UTR and flanking 3' region. 
FIG.3 is a sketch of the plasmidpUCWAP5 cassette vector 
containing the WAP fragment of puCWAP4 with added Not 
I linkers. 
FIG. 4 is a sketch of the puCWAP5 plasmid incorporating 
a polynucleotide encoding the FIBAC. 1 chain. 
FIG. 5 is a sketch of the puCWAP5 plasmid incorporating 
a polynucleotide encoding the FIB Bf 1 chain. 
FIG. 6 is a sketch of the puCWAP5 plasmid incorporating 
a polynucleotide encoding the FIBGY 1 chain. 
FIG. 7 shows the family tree of transgenic mice that have 
incorporated into their genome DNAS encoding FIB genes. 
FIG. 8 is a schematic of the means for separating endog 
enous from rhFIB in mouse milk whey and plasma. 
FIG. 9 shows a Western blot under non-reducing condi 
tions of transgenic rhFIB in mouse whey and plasma. 
FIG. 10 shows the same experiment as in FIG. 9, except 
that the gel was run under reducing conditions. 
FIG. 11 shows an SDS-PAGE separation of rhFIB after 
digestion with thrombin. 
FIG. 12 shows the results of assays for thrombinopeptide A 
after digestion by thrombin of rhFIB. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
An approach has been discovered to producing non-hu 
man, transgenic mammalian animals that are genetically 
engineered to secrete, into readily accessible body fluids Such 
as milk, blood and urine, recombinant holofibrinogen (for 
example, rhFIB), individual subunit chain polypeptides of 
FIB, and modified FIB subunit chains in amounts and in 
forms that are Suitable for treating humans with genetic or 
acquired deficiencies of the normal protein. 
Glossary 
The term “animal’ here denotes all mammalian animals 
except humans. It also includes an individual animal in all 
stages of development, including embryonic and fetal stages. 
A “transgenic' animal is any animal containing cells that bear 
genetic information received, directly or indirectly, by delib 
erate genetic manipulation at the Subcellular level. Such as by 
microinjection or infection with recombinant virus. 
“Transgenic’ in the present context does not encompass 
classical crossbreeding or in vitro fertilization, but rather 
denotes animals in which one or more cells receive a recom 
binant DNA molecule. Although it is highly preferred that 
this molecule be integrated within the animal’s chromo 
Somes, the present invention also contemplates the use of 
extrachromosomally replicating DNA sequences, such as 
might be engineered into yeast artificial chromosomes. 
The term “germ cell line transgenic animal' refers to a 
transgenic animal in which the genetic information has been 
taken up and incorporated into a germ line cell, therefore 
conferring the ability to transfer the information to offspring. 
If Such offspring in fact possess Some or all of that informa 
tion, then they, too, are transgenic animals. 
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The information to be introduced into the animal is pref 
erably foreign ("heterologous') to the species of animal to 
which the recipient belongs, but the information also may be 
foreign only to the particular individual recipient, or genetic 
information already possessed by the recipient. In the last 
case, the introduced gene may be differently expressed than is 
the native gene. 
By “holofibrinogen' is meant the mature, fully glycosy 
lated, physiologically functional fibrinogen. Unless specified 
otherwise, the abbreviations FIB or hFIB or hrFIB as used 
herein will refer to this holoprotein. 
Animals 
The transgenic animals of this invention may be any ani 
mal, other than human, that produces milk, blood serum, and 
urine. Farm animals (pigs, goats, sheep, cows, horses, rabbits 
and the like), rodents (such as mice), and domestic pets (for 
example, cats and dogs) are included in the scope of the 
present invention. 
Stable Integration of DNA Constructs in Animal Genome 
It is highly preferred that the transgenic animals of the 
present invention be produced by introducing into single cell 
embryos appropriate polynucleotides that encode human 
holoFIB, or individual subunit chain polypeptides or modi 
fied products thereof, in a manner Such that these polynucle 
otides are stably integrated into the DNA of germline cells of 
the mature animal and inherited in normal mendelian fashion. 
Advances in technologies for embryo micromanipulation 
now permit introduction of heterologous DNA into fertilized 
mammalian ova. For instance, totipotent or pluripotent stem 
cells can be transformed by microinjection, calcium phos 
phate mediated precipitation, liposome fusion, retroviral 
infection or other means, the transformed cells are then intro 
duced into the embryo, and the embryo then develops into a 
transgenic animal. In a preferred method, developing 
embryos are infected with a retrovirus containing the desired 
DNA, and transgenic animals produced from the infected 
embryo. In a most preferred method, however, the appropriate 
DNAs are coinjected into the pronucleus or cytoplasm of 
embryos, preferably at the single cell stage, and the embryos 
allowed to develop into mature transgenic animals. Those 
techniques as well known. For instance, reviews of standard 
laboratory procedures for microinjection of heterologous 
DNAS into mammalian (mouse, pig, rabbit, sheep,goat, cow) 
fertilized ova include: Hogan et al., MANIPULATING THE 
MOUSE EMBRYO, Cold Spring Harbor Press, 1986: 
Krimpenfort et al., Bio/Technology 9: 86 (1991); Palmiter et 
al., Cell 41:343 (1985); Kraemeret al., GENETIC MANIPU 
LATION OF THE EARLY MAMMALIAN EMBRYO, Cold 
Spring Harbor Laboratory Press, 1985; Hammer et al., 
Nature, 315: 680 (1985); Purcel et al., Science, 244: 1281 
(1986); Wagner et al., U.S. Pat. No. 5,175.385; Krimpenfort 
et al., U.S. Pat. No. 5,175,384, the respective contents of 
which are incorporated by reference. The human FIB or FIB 
Subunit genes can be obtained by isolating them from an 
appropriate genomic source (i.e., human liver, which is the 
natural organ for production of this protein) by alternate 
methods which include preparation of cDNAs from isolated 
mRNA templates, direct synthesis, or some combination 
thereof. The cDNAs encoding individual FIB chains can be 
fused, in proper-reading frame, with appropriate regulatory 
signals as described in detail below, to produce a genetic 
construct that is then amplified, for example, by preparation 
in a bacterial vector, according to conventional methods. See, 
for example, the standard work: Sambrook et al., MOLECU 
LAR CLONING: A LABORATORY MANUAL, Cold 
Spring Harbor Press, 1989, the contents of which are incor 
US 7,435,869 B2 
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porated by reference. The amplified construct is thereafter 
excised from the vector and purified for use in producing 
transgenic animals. Purification can be accomplished by 
means of one or more cycles of anionic HPLC: alternate 
techniques include ultracentrifugation through a Sucrose or 
NaCl gradient, gel electroelution followed by agarose treat 
ment and ethanol precipitation, or low pressure chromatog 
raphy. Purification by several cycles of HPLC allows for 
remarkably high transformation frequencies, on the order of 
20% or more in both mice and pigs. 
Although the present invention preferably entails the use of 
DNA constructs that produce the desired or native human FIB 
per se, the desired protein may also be produced as a fusion 
protein containing another protein. For example, the desired 
recombinant FIB protein of this invention may be produced as 
part of a larger recombinant protein in order to stabilize the 
desired protein or to make its purification from milkfaster and 
easier. The fusion partners are then separated chemically or 
enzymatically, and the desired FIB isolated. Production of a 
fusion product between FIB and B-lactoglobulin (BLG) or 
between FIB and another milk protein are contemplated. 
The rhEIB may also be produced having the identical 
sequence as the native molecule, or it may be produced as a 
fragment or derivative. A variety of modified rhFIB or sub 
units thereof can be produced by altering a cloned DNA using 
the well-known techniques of in vitro mutagenesis such as 
those set out in the references above. 
Production of transgenic animals containing the gene for 
human FIB involves the use of cDNA or genomic DNA that 
encodes the C, B, and Y chains of hFIB. See Rixon et al., 1983, 
and Chung et al., 1983, supra. The full-length base sequence 
of each chain is provided in these references, the contents of 
which therefore are incorporated by reference. 
DNA constructs useful in the present invention provide a 
double stranded DNA sequence encoding FIB operably 
linked to all of the cis-acting signals necessary for mammary 
gland-specific expression of this protein, post-translational 
glycosylation of two of the three sets of chains of FIB (B?3 and 
GY), secretion of FIB into milk or other body fluids, and 
expression of full biological activity. As set out above, poly 
nucleotides encoding FIB or FIB subunit chains suitable for 
use in the invention can be isolated by Standard techniques 
starting from the known polynucleotide sequences. 
Modified FIBDNA sequences also can be employed in this 
invention. Useful modifications within this context include, 
but are not limited to, those that alter post-translational modi 
fications, size or active site of FIB, or that fuse this protein or 
portions thereofto another protein. Such modifications can be 
introduced into the protein by techniques well known in this 
art, Such as by synthesizing modified genes by ligation of 
overlapping oligonucleotide or introducing mutations into 
the cloned genes by, for example, oligonucleotide-mediated 
mutagenesis. See, for example, Ebert et al., Bio/Technology 9: 
835 (1991), Denman et al., loc. cit.: 839 (1991), and Gerardet 
al., Science 248: 1421 (1991), for details of procedures for 
site mutagenesis of proteins. One or more FIP glycosylation 
sites can be eliminated or changed by site mutagenesis, for 
instance. Another variant might be a chimeric FIB having a 
tissue growth factor as protease inhibitor peptide attached to 
the nascent FIP polypeptide during transgenic biosynthesis or 
by co-current translation. The assembly of the complex hex 
americ structure may be exploited to include a guest mol 
ecule, but while maintaining recognition of the FIB complex 
for secretion. Specific changes of entire domains within FIB 
could be used to impact specialized activity of other mol 
ecules, but still remain the hexameric structure required for 
secretion. 
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The cis-acting regulatory regions useful in the invention 
include the promoter that drives expression of the FIB or FIB 
Subunit chain genes. Highly preferred are promoters that are 
specifically active in mammary gland cells and that involve 
milk proteins. Among Such promoters, highly preferred are 
the whey acidic protein (WAP), short and long C, B and kappa 
casein, C.-lactalbumin and B-lactoglobulin (“BLG”) promot 
ers. Promoters may be selected on the basis of the protein 
compositions of various milks. 
For example, the WAP and BLG promoters are particularly 
useful with transgenic rodents, pigs and sheep. The rodent 
WAP short and long promoters have been used to express the 
rat WAP gene, the human tA gene and the CD4 gene, while 
the sheep BLG promoter has been used to express the sheep 
BLG gene, the human alpha-1-antitrypsin gene and the 
human Factor IX gene. For reviews, see Paleyanda et al. in 
RECOMBINANT TECHNOLOGY IN HEMOSTASIS 
AND THROMBOSIS (eds. Hoyer et al.), Plenum Press, NY 
(1991), at page 197; Clarket al., TIBTECH 5:20 (1987), the 
respective contents of which are incorporated by reference. 
Preferred among the promoters for carrying out the present 
invention are the rodent casein and WAP promoters (see, for 
example, Rosen, U.S. Pat. No. 5,304,489, and Meade, U.S. 
Pat. No. 4,873.316) and the casein, C.-lactalbumin and BLG 
promoters (Strijkeret al., U.S. Pat. Nos. 5,322,775 and 5,366, 
864) from porcine, bovine, equine and ovine (pigs, sheep, 
goats, cows, horses), rabbits, rodents and domestic pets (dogs 
and cats); accordingly, the respective contents of the afore 
mentioned patents are incorporated by reference. The genes 
for these promoters have been isolated and their characteriza 
tions published. For reviews see Clarket al. (1987), supra, and 
Henninghausen, Protein Expression and Purification 1: 3 
(1990). The mouse WAP promoter is commercially available: 
see ATCC catalogueno. 63005 (2d ed., 1991), Rockville, Md. 
The promoter may be isolated by carrying out conventional 
restriction endonuclease and Subcloning steps. A preferred 
mouse WAP promoter can be isolated as a 2.6 kb EcoR1 
Kpn1 fragment which is immediately 5' to the WAP signal 
sequence. The “long WAP promoter the 5' 4.2 kb Sau3A 
Kpnl promoter of the mouse WAP gene, or a fragment 
thereof is also suitable for carrying out the present inven 
tion (see, Paleyanda et al., 1991 above; Henninghausen, 1990, 
above). 
Important to the present invention are regulatory sequences 
that direct secretion of proteins into milk and/or other body 
fluids of the transgenic animal. In this regard, both homolo 
gous and heterologous regulatory sequences are useful in the 
invention. Generally, regulatory sequences known to direct 
the secretion of milk proteins, such as either signal peptides 
from milk for production of individual FIB subunit chain 
polypeptides or the nascent target polypeptide for production 
of the holoFIB, can be used. Signal sequences also can be 
used in accordance with this invention that direct the secre 
tion of expressed proteins into other body fluids, particularly 
blood and urine, such as signal sequences for coagulation 
proteins such as protein C and Factor VIII. 
Unexpectedly, it has been found that a trigenic animal can 
efficiently express three separate transgenes which do not 
have a signal peptide operably linked between promoter and 
encoding DNA sequences, but still direct synthesis and secre 
tion of a assembled recombinant human fibrinogen protein in 
milk of a transgenic animal. This occurs in a temporally 
regulated way as to enable a complex asymmetric assembly 
of the fibrinogen polypeptides which nascent polypeptides 
then enables subsequent secretion of the hexameric, 340 kDa 
protein in milk. It is important to note that, in general, mam 
malian cells do not efficiently secrete separate fibrinogen 
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chains. See Danishefsky et al., Biochim. Biophys. Acta 1048: 
202 (1990), and Hartwig et al., J. Biol. Chem., 266: 6578 
(1991). This phenomenon has been explained by Danishefsky 
et al. to be a consequence of proper folding rather than the 
presence of a specific domain within one of the component 5 
chains that may be a prerequisite for fibrinogen secretion; 
this, since neither of the three chains of fibrinogen by them 
selves have the integral signal for secretion. A separate, iden 
tifiable signal sequence therefore does not appear to exist in 
any of the individual C, B and Y polypeptides (and, hence, 10 
there is no signal sequence encoded immediately preceding 
the coding sequence for any of the nascent polypeptides in the 
cDNA or genomic sequences offibrinogen chains) for direct 
ing secretion. Importantly, it has been discovered discovered 
that it is not necessary to add any coding for milk protein or 15 
other specific signal sequences to the fibrinogen cDNAS used 
to make trigenic mice, pigs and cows which secrete properly 
folded and active transgenic hFIB. The highly preferred con 
structs consist of three separate transgenes; each transgene 
has the 2.5 kb-WAP-promoter ligated directly to the native 20 
cDNA for one the C.B., and Y FIB polypeptides with no inter 
Vening signal sequence. 
As noted above, there is no requirement for a coding DNA 
for signal peptide sequences in each of the present three FIB 
polynucleotide constructs when producing holoFIB. The 25 
prior art does not suggest this fact, nor does it presage a 
properly folded, complex recombinant fibrinogen structure 
which specifically enables the mammary tissue Golgi trans 
port system to efficiently secrete the assembled FIB. The 
present examples have three salient features which show that 30 
indeed the mammary tissue can perform Such a task. First, the 
levels of rFIB found are consistent with the stable expression 
levels found for prior examples of 2.5 kb 5’-WAP promoter 
cDNA single gene, single polypeptide expressions in the milk 
of transgenic mice (i.e., about 1-100 g/ml, Hennighausen et 35 
al., above). Second, the transgenic mice secrete fibrinogen 
without involution as indicated by their normal lactation and 
pup weight gain. Third, the recombinant fibrinogen secreted 
is physiologically active. Thus, in combination, these results 
Suggest that no significant intracellular buildup of assembled 40 
fibrinogen occurs in the mammary epithelium which is suffi 
cient to halt lactation. Likewise, no appreciable secretion of 
individual unassembled polypeptides occurred in trigenic-C. 
B.Y-fibrinogen mice. 
In contrast to the trigenic animal, it appears that a signal 45 
peptide is needed for each cDNA sequence encoding C, B and 
Y if the unassembled, individual chains are to be efficiently 
secreted from the mammary epithelium. 
Among the useful sequences that regulate transcription, in 
addition to the promoters discussed above, are enhancers, 50 
splice signals, transcription termination signals, and polyade 
nylation sites. Particularly useful in this regard are those that 
increase the efficiency of the transcription of the genes for 
fibrinogen in the mammary gland cells of the transgenic ani 
mals listed above. Preferred are transcription regulatory 55 
sequences for proteins highly expressed in the mammary 
gland cells (see above). 
Preferably, the expression system or construct of this 
invention also includes a 3' untranslated region downstream 
of the DNA sequence encoding the desired recombinant pro- 60 
tein, or the milk protein gene used for regulation. This region 
apparently stabilizes the RNA transcript of the expression 
system and thus increases the yield of the desired protein. 
Among the 3' untranslated regions useful in this regard are 
sequences that provide a polyA signal. Such sequences may 65 
be derived, for example, from the SV40 small tantigen, from 
the casein 3' untranslated region, and from other 3' untrans 
8 
lated sequences well known in this art. Preferably, the 3' 
untranslated region is derived from a milk-specific protein. 
The stabilizing effect of this region's poly A transcript is 
important in stabilizing the mRNA of the expression 
sequence. Also important in increasing the efficiency of 
expression of FIB are ribosome binding sites. Likewise, 
sequences that regulate the post-translational modification of 
FIB subunits are useful in the invention. 
Pursuant to the present invention, therefore, a double 
stranded chimeric DNA, including genes that code for the FIB 
Subunit chains and that are operably linked to cis-acting regu 
latory sequences which promote efficient expression of the 
former in milk and/or other body fluids, are introduced into an 
embryo, where they are integrated into the embryonic 
genome and become part of the inheritable genetic endow 
ment of all of the animals cells, including the germline cells, 
of the adult which matures from the embryo. The FIB thus 
expressed and secreted into milk is immunologically reactive, 
as measured by an ELISA assay described below. 
Where the synthesis of a FIB subunit chain may be limiting 
in the production of-the holoprotein, expression of this chain 
an be increased by placing the gene in a different genomic 
locus. This otherlocus can contain a DNA sequence under the 
same or a different regulatory sequence than the other two 
FIB sequences. 
In a particularly preferred embodiment the transgenes of 
the invention generally consist of milk protein upstream and 
downstream and flanking sequences in combination, sepa 
rately, with each of the three translated portions of the cDNA 
sequences representing the three FIB subunit chains. A native 
5'-WAP regulatory sequence ending in an accessible restric 
tion site immediately before/at the ATG codon may be ligated 
to each of the respective restriction sites which occur at the 
ATG of translatable sequences with no linker sequences 
derived from the chains of human FIB. A restriction site may 
be made through site mutagenesis of three bases located in 
each 3'-untranslatable sequences of the three FIB cDNAs. 
This preserves the stop sequence, while adding a restriction 
site immediately after each of the translatable sequences of 
the FIB cDNAs. Each of the combined 5'-regulatory and FIB 
translatable sequences which end in a particular restriction 
site then can be ligated to a corresponding restriction site 
which occurs at the beginning of the 3'-untranslated region of 
WAP and adjoining WAP 3'-flanking region. This construc 
tion motifenables native 5'-regulatory and 3'-UTR of the milk 
protein genes to be immediately juxtaposed without interven 
ing sequences (but see above relating to the insertion of the 
BB gene at a different locus). Particular restriction sites at the 
ends of all constructs may be selected in order to facilitate 
concatenation of AC, BB and GY constructs into a single 
domain within the animal genome. 
Although the foregoing, general description of the DNA 
constructs within the present invention relates in several 
places to the WAP promoter, it is emphasized that other suit 
able promoters (see above for discussion) can be ligated to the 
fibrinogen encoding polynucleotides in a similar manner. By 
way of illustration, the following discussion describes the use 
of the bovine lactoglobulin (“BLG”) promoter to increase the 
efficiency of expression of FIB and FIB-BLG fusion proteins 
in mammary glands. 
Using techniques described above, fibrinogen encoding 
cDNA may be inserted into an ovine BLG gene. In order to 
produce Such a construction, for instance, the 11.2 Kbp ovine 
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BLG gene may be modified to possess a unique EcoRV site 
upstream of the initiator ATG codon in the vectorpUCXSRV. 
The sequence around this region is changed as follows: 
PWI MetLys Seq. ID No. 1 
Natural CCCCAGCTGCAGCCATGAAG 
EcoRV MetLys Seq. ID No. 2 
pUCXSRV CCCCAGGGATATCCCTGCAGCCATGAAG 
This allows the cloning of bluntend fragments upstream of 
the BLG gene. The 1.5 kbp fragment from a plasmid (e.g., 
pWAPFIB) which contains a cDNA encoding human fibrino 
gen is isolated, blunt ends are generated with T4DNA poly 
mer, and the product is ligated to EcoRV-cleaved puCXSRV. 
Following transformation of E. coli with this plasmid, clones 
that are produced can be characterized by restriction analysis 
of plasmid DNA prepared by a mini-prep method and by 
determination of the nucleotide sequence around the 5' and 3' 
cloning junctions for the DNA. Clones having the desired 
structure can be used to produce transgenic rodents, pigs, 
sheep, cows, horses and other farm animals and domestic pets 
(cats and dogs) that secrete a FIB-BLG fusion product into 
their biological fluids as described below. 
A hFIB genomic sequence also may be fused to the ovine 
BLG promoter illustrated in the following discussion. DNA 
sequences encoding ovine BLG in plasmid puCXSRV are 
deleted to generate a vector containing only ovine BLG pro 
moter sequences(pUCSV). As with puCSRV, blunt-ended 
fragments can be fused to this promoter region by ligation to 
a unique EcoRV site. The sequences 5' to this site are identical 
in both plasmids. 
Genomic FIB sequences of greater than about 15 kbp can 
be introduced into transgenic animals, despite-their length, 
through the use of cosmids with overlapping FIB sequences, 
whereupon the necessary assembly of an entire genomic 
polynucleotide encoding hEIB is achieved by homologous 
recombination in vivo after microinjection into an embryo 
cell. In constructs useful in the foregoing example, a plasmid 
in which the FIB genomic sequences are fused to ovine BLG 
3' flanking sequences just after the fibrinogen translation ter 
mination codon to ensure proper transcription, termination 
and polyadenylation. The hFIB gene fused to ovine BLG 3' 
flanking sequences is excised from the plasmid, the 3' over 
hangs repaired using Klenow enzyme, and the product ligated 
to EcoRV-cleaved PUCSR. Following transformation of E. 
coli, the resulting clones are characterized by restriction DNA 
analysis and by determining the nucleotide sequences around 
the 5' and 3' cloning junctions. Clones having the desired 
structure may be introduced into fertilized animal ova for 
production of transgenic animals. 
A variety of vectors based on the BLG gene may be con 
structed. In constructs based on this approach, the sequences 
encoding the ovine BLG protein are deleted, but the 5' pro 
moter sequences are retained. Each may possess a different 
complement of introns from the ovine gene and a unique 
EcoRV site allowing the cloning of blunt ended fragments 
between the promoter and 3' flanking region of the gene. 
However, each contains the BLG promoter, the EcoRV site 
and the BLG 3'-flanking sequence. For each recombinant, the 
1.5 kbp. KpnI fragment from pWAPFIB is isolated, bluntends 
generated as above, and the product ligated to EcoRV-cleaved 
vector sequences. Those constructs with the proper struc 
tures, determined as described above, can be used to express 
FIB in the biological fluids of transgenic animals. 
A notable result is obtained with doubly-transgenic mice 
that are produced having native BLG genomic sequences 
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which were injected as separate constructs to be concatenated 
in vivo, as additional flanking sequences to the BLG target 
cDNA construct (such as, BLG promoter-Intron I-EcoRV 
Intron VI-BLG 3' flank plus BLG). In particular, such mice 
give higher expression more frequently than do mice pro 
duced using constructs of the BLG promoter-FIB cDNA 
BLG gene or BLG promoter-FIB genomic (thBLG 3' end). 
Intact or native BLG genomic sequences that are preligated to 
the BLG-cDNA target may give the same advantage. The 
same principle applies, mutatis mutandis, to WAP genomic 
Sequences. 
Isolation of Milk from Lactating Transgenic Animals 
Obtaining milk from a transgenic animal according to the 
present invention is accomplished by conventional means. 
See, for example, McBurney et al., J. Lab. Clin. Med. 64: 485 
(1964); Velander et al., Proc. Nat'l Acad. Sci. USA 89:12003 
(1992), the respective contents of which are incorporated by 
reference. Fibrinogen or Subunit chains or protein products 
thereof can be isolated and purified from milk or urine by 
conventional means without deleteriously affecting activity. 
A highly preferred method entails a combination of anion 
exchange and immunochromatographies, cryoprecipitations, 
and zinc ion-induced precipitation of either whole milk or 
milk whey (defatted milk) proteins. For these techniques, see 
Bringe et al., J. Dairy Res. 56:543 (1989), the contents of 
which is incorporated herein by reference. 
Milk is known to contain a number of proteases that have 
the potential to degrade foreign proteins. These include in the 
main an alkaline protease with tryptic and chymotryptic 
activities, a serine protease, a chymotrypsin-like enzyme, an 
aminopeptidase and an acid. protease. Clark et al. (1987), 
supra. It may be desirable, therefore, to protect newly 
secreted FIB or subunit chains thereof against proteolytic 
degradation. Such precautions include rapid processing of the 
milk after collection and addition to the milk of well known 
inhibitors of proteolysis, such as are listed in SIGMA 
CHEMICAL CO. CATALOG, 1993 edition, at page 850. 
Detection and Quantification of Transgenic FIB 
The present inventors have used two sandwich ELISA 
formats to detect and quantify FIB in milk whey. One tech 
nique is a polyclonal antibody capture/FIB/monoclonal anti 
body detection system (“P/M) and the other which uses 
polyclonal antibodies both for capture and for detection (“P/ 
P”). Both methods are described below. The P/M system 
benefits from greater specificity for hFIB as it recognizes only 
one epitope of about 6 to 20 amino acids in length specific to 
hFIB. However, because the P/M system recognizes only a 
single epitope, detection sensitivity is reduced. In contrast, 
the P/P system will provide less specificity as it recognizes 
many epitopes, but at the same time will provide greater 
detection sensitivity. As these multiple epitopes include 
epitopes conserved between mouse and human FIB, the back 
ground “FIB' signal is increased when measuring rhFIB in 
mouse milk by the P/P system. Detailed sandwich ELISA 
procedures are provided in EXAMPLE 7 below. 
Purification and Biological Activity of Secreted Recombinant 
Fibrinogen 
Mammalian proteins associated with hemostasis are well 
conserved with respect to structure and function and thus it is 
necessary to both identify and purify rFIB from host body 
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fluids. To establish that the FIB secreted in the milk of trigenic 
animals is indeed authentic, i.e., physiologically active, het 
erologous FIB, a number of well known, standard techniques 
may be carried out; these are listed below: 
Physical Techniques 
(1) Physical separation and identification. A sequence of 
ion exchange chromatography and Zn’-- selective precipita 
tion achieves two main goals: the reduction of background 
protein (i.e., host FIB) from milk and an efficient isolation of 
rhFIBaway from contaminating host FIB. Host FIB is present 
to a very small extent from natural passover of serum proteins 
into milk, but it is predominately due to injury of the mam 
mary tissue from the milk collection process. Over half of the 
background milk proteins can be removed by anion exchange 
chromatography. Over 75% of the casein will be removed by 
the Zn-- selective precipitation process. The resulting rhFIB 
will be about 20-30% pure at this stage with an overall yield 
of about 50%. Control host milk whey serves as a negative 
human FIB control, and control whey doped with authentic 
human FIB serves as a positive control for human FIB. Trans 
genic whey serves as the source of recombinant FIB. The 
non-doped control whey contains host FIB that primarily 
partitions into a second 24 mM Zn-- supernatant fluid. Only 
about 1-3% of the FIB present in the final purified human or 
rhFIB samples will be host FIB. Thus, the Zn-- selective 
procedure enables an efficient separation of rhFIB from host 
FIB. 
(2) Silver staining of SDS-PAGEgels of isolated rhFIB. 
(3) Western blot analyses of isolated rhFIB. 
(4) Fibrinopeptide A detection by EIA in thrombin-treated 
samples. 
Biochemical Tests 
(5) Using ELISA signals (using detection by polyclonal 
anti-human fibrinogen antisera found in the Supernatants after 
centrifugation to remove precipitates and/or clots) to track the 
consumption of isolated rhFIB by human thrombin. 
(6) Determination of the apparent molecular weights of the 
assembled FIB molecule and of the separate C.B., and Y chains 
found under reducing conditions. 
(7) The formation of a fibrin-like clot after treatment of the 
isolated rhEIB with human thrombin. 
(8) The formation of C.B., and Y fibrin chains in these same 
clots. 
(9) The release of fibrinopeptide A to confirm biological 
activity of isolated rhFIB by conversion to fibrin upon reac 
tion with human thrombin. 
For sources of these well-known techniques see, for 
example, Hartwig et al., J. Biol. Chem., 266: 6578 (1991); 
Koopman et al., J. Biol. Chem., 266: 13456 (1991); Lonnerdal 
et al., J. Appl. Biochem., 4: 203 (1982); Farrell et al., Bio 
chem., 30: 9414 (1991); Goding, MONOCLONAL ANTI 
BODIES: PRINCIPLES AND PRACTICE, Academic Press, 
NY: Bolyard et al., Gene 66: 183-(1988); Hartwig et al., J. 
Biol. Chem., 266: 6578 (1991); Roy et al., loc. cit., 266: 4758 
(1991); Dempfie et al., Thrombosis Res., 46: 19 (1987); 
Dempfie et al., loc. cit., 48: 223 (1987); and Yu et al., Bio 
chem. Biophys. Res. Commun., 96: 1032 (1980), the respec 
tive contents of which are incorporated by reference. 
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The present invention is further described by reference to 
the following illustrative examples. 
EXAMPLE 1. 
WAP-Fibrinogen cINA Constructs for Expression 
of Fibrinogen in Transgenic Animals 
Construction of Cassette Vectors 
FIB subunit chain DNAs, tissue-specific promoters, and 
secretion signal sequences were obtained from sources 
described above. FIB subunit chain cDNAs were cloned into 
a modified puC 18 vector, and grown up in E. coli JM109. 
A puC18 vector (GIBCO-BRL, Gaithersburg, Md.) was 
digested with HindIII+EcoRI restriction endonucleases, 
blunted with T4DNA polymerase in the presence of 100 mM 
dNTPs, and a Not I linker was ligated into the former HindIII 
EcoRI multiple cloning site. This modified puC fragment 
was additionally digested with Not I+ enzyme to remove 
extra (multiple copies) Not linker sequences arising from 
ligation, and then religated and grown up in E. coli JM 109. 
This procedure modified the puC18 vector by removing the 
entire multiple cloning region of puC18 (including the Kpn I 
site) and replacing it with a Not I restriction site. The new 
vector was designated puCNot1+. 
A pUC vector containing -2.6 kbp of WAP 5' promoter 
region, -1.3 kbp of WAP3' UTR and flanking 3", but no WAP 
coding or intronic regions was constructed (designated cas 
sette vector pUCWAP4, FIG. 2; see WAP gene, FIG. 1, and 
cassette vector puCWAP5, FIG. 3). The entire murine WAP 
gene including 2.6 kb of 5' untranslated sequence and 3' 
untranslated region may be obtained from Dr. I. Hen 
nighausen, National Institutes of Health, Bethesda, Md. See, 
Campbell et al., Nucleic Acids Res., 12:8685 (1984). The 
WAP fragment contained within the WAP4 vector contains a 
-2.6 kbp WAP promoter 5' region beginning at EcoRI#1 and 
ending at the translational start site of WAP which is imme 
diately downstream of the unique Kipn I endonuclease restric 
tion site (see FIG. 1). To this KpnI site was ligated a fragment 
of-1.3 kbp of WAPUTR and flanking 3' sequence. This WAP 
3' DNA included the region from immediately downstream of 
the WAP stop codon down to the EcoRI#2 site. The WAP 
fragment contained in WAP4 was excised from the puC 
vector using EcoRI, and then blunted, and NotI linkers were 
added, further trimmed by NotIdigestion, and ligated into the 
pUCNotI+ plasmid which had been linearized with NotI 
restriction endonuclease. The resulting plasmid was desig 
nated puCWAP5 (see FIG. 3). 
Amplification by PCR of Fibrinogen Subunit Chain cDNAs 
Each of the cDNAs for AC, Bf3, and GY chains for human 
fibrinogen were individually modified and amplified by poly 
merase chain reaction (PCR) to create KpnI endonuclease 
restriction sites on their 5' and 3' ends. The 5' KpnI site was 
engineered by PCR using the primers containing the 6 base 
sequence (GGTACC shown underlined in Table 1) that 
immediately flanks the ATG start codon in the cDNAs of AC. 
BB, and GY chains for hFIB. After amplification, the ends of 
the extension using PCR products were blunted by T4-poly 
merase (in the presence of deoxynucleosidetriphosphates to 
inhibit processive exonuclease activity. In a similar fashion, a 
KpnI site was engineered by site modification into the 6 base 
sequence GGTACC shown underlined in Table 1 immedi 
ately flanking the stop sequence in the 3' UTR of each cDNA 
for AC, Bf3, and GY chains for hFIB. The complement of the 
stop sequences is shown in bold in the 3' primers in Table 1. 
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TABLE 1. 
Oligonucleotides for Amplifying FIB Subunit Chain 
cDNA 5 
Seq. ID No. 3 AC. 5' GCTAGGTACCATGTTTTCCATGAGGATCGT 
Seq. ID No. 4 AC 3' CAGTGGTACCCTAGACAGGGCGAGATTTAG 
Seq. ID No. 5 B? 5' GCTAGGTACCATGAAAAGAATGGTTTCGTG 10 
Seq. ID No. 6 Bf 3' CAGTGGTACCCTATTGCTGTGGGAAGAAGG 
Seq. ID No. 7 GY 5' GCTAGGTACCATGAGTTGGTCCTTGCACCC 
15 
Seq. ID No. 8 GY 3' CAGTGGTACCTTAAACGTCTCCAGCCTGTT 
GGTACC = KipnI site 
ATG = start codon 
CTA and TTA = stop codon 2O 
Construction of puC Plasmids Containing 
Fibrinogen Subunit Chain cDNA 
25 
The blunted PCR products of the cDNAs for the BBand Gy 
chains of human fibrinogen were digested with Kpnl restric 
tion endonuclease. In the case of the AC chain, the PCR 
product was blunt-end cloned into puCNotI+ (which had 
been digested with NotI and blunted with T4 Polymerase) 
prior to partial Kpndigestion. This intermediate cloning and 
partial digestion step was necessary to generate intact coding 
fragment due to the presence of an internal KpnI site within 
the AC. chain cDNA. The intact AC. chain cDNA fragment was 35 
selected by gel electrophoresis, and cloned into the KpnI site 
at the junction between the WAP 5' promoter and WAP 3' 
UTR/flanking sequences within the puCWAP5 plasmid. The 
KpnI-digested PCR products from Bf3 and GY chains for 
human fibrinogen were each directly cloned into a 
pUCWAP5 plasmid at the KpnI site. Separate electroporation 
transformation reactions were done on E. coli using each of 
the three puCWAP5/fibrinogen cDNA preparations, and 
colonies were picked and grown up in TB amplicillin broth. 45 
Plasmid preparations from these colonies were analyzed by 
restriction enzyme digestion and gel electrophoresis. The 
correct size and orientations were selected and one clone for 
each WAP-fibrinogen cINA construct was sequenced at the 
WAP promoter 5':fibrinogen cDNA and fibrinogen cDNA: 50 
WAP 3' UTR and flanking junctions. Schematics summariz 
ing the construction of the WAP-AC. (about 5.8 kbp). -Bf 
(about 5.4 kbp), and -GY (about 5.2 kbp) cDNA plasmid and 
linearized transgenes for human fibrinogen are given in FIGS. ss 
4, 5, and 6, respectively. 
30 
40 
EXAMPLE 2 
Preparation of DNAs for Microinjection 60 
The intact and linearized WAP 5' promoter/fibrinogen 
cDNA/WAP 3' UTR and flanking fragments were excised 
from each puCWAP5 plasmids by NotI restriction endonu- as 
clease digestion and purified by low melting point agarose 
electrophoresis. The DNA:agarose band was cut from the gel 
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slab. The agarose band was then treated with agarase to 
degrade and remove agarose contamination. After digestion, 
the solution containing the cDNA was brought to 10 mM 
Mg2+, 20 mM EDTA and 0.1% SDS and then extracted with 
phenol/chloroform. DNA was precipitated from the aqueous 
layer with 2.5 volumes of ethanol in the presence of 0.3 M 
sodium acetate at -20°C. overnight. After centrifugation, the 
pellet was washed with 70% ethanol, dried, and each of the 
constructs was resuspended and dissolved in Brinster micro 
injection buffer to a total (C, B, plus Y) concentration of about 
1.2 to 5 lug/ml. Brinster et al., Proc Natl. Acad. Sci. USA 
82:4438 (1985), incorporated by reference. 
EXAMPLE 3 
Transgenic Mice 
Transgenic mice were produced essentially as described by 
Hogan et al., Manipulating The Mouse Embryo, Cold Spring 
Harbor Press, 1986, incorporated by reference. The proce 
dures employed are outlined below. 
Glass needles for micro-injection were prepared using a 
micropipet puller and microforge. Injections were performed 
using a Nikon microscope having Hoffman Modulation Con 
trast optics, with Narashigi micromanipulators and a pico 
injector driven by N (Narashigi). 
Fertilized mouse embryos were surgically removed from 
the oviducts of superovulated female CD-1 mice and placed 
into M2 medium. Cumulus cells were removed from the 
embryos with hyaluronidase at 300 ug/ml. The embryos were 
then rinsed in new M2 medium, and transferred into M16 
medium for storage at 37° C. prior to injection. 
Stock solutions containing about 1.2 g/ml (having about 
0.4 ug/ml each of the linearized constructs containing the AC. 
BB, and GY chains cloNAs for human fibrinogen, or about 
60-70 copies/pl of each construct) were prepared and micro 
injected into the pronuclei of 1 cell mouse embryos. In addi 
tion, stock solutions containing about 5 g/ml total DNA 
(having about 1.7 Lig/ml of linearized constructs containing 
each of the AC, Bf3, and GY chains cDNAs for human fibrino 
gen or about 200 copies/pl of each construct) were prepared 
and microinjected into the pronuclei of 1 cell mouse embryos. 
After injecting the DNA solution into the male pronucleus, 
embryos were implanted into avertin-anesthetized CD-1 
recipient females made pseudo-pregnant by mating with 
vasectomized males. About 25-30 microinjected mouse 
embryos per recipient were transferred into pseudopregnant 
females. Embryos were allowed to come to term and the 
newborn mice were analyzed for the presence of the trans 
gene by PCR using murine WAP and a FIB-specific primeras 
described below. 
Table 2 summarizes the embryo transfer data from an 
experiment that produced transgenic fibrinogen-producing 
mice. Separate PCR analysis for detection of each of the 
cDNAs of fibrinogen was done on DNA purified from biop 
sied tail tissues by the method shown in Example 4 below. The 
oligonucleotide primers shown in Table 3 were used to detect 
each of the FIB cDNAs. Detection of each chain required a 
WAP oligonucleotide (no. 1 in Table 3) and one of the other 
oligonucleotides (Nos. 2, 3 or 4). 
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TABLE 2 
Transfers of Fibrinogen Constructs 
Thirty transfers with the FIB constructs were performed. The three 
Subunit chain constructs were coinjected at total DNA concentrations 
of 1.2 g/ml and 5 g/ml or 200 total copies pland 800 total 
copies.pl, respectively. Fourteen transfers were made with 
1.2 g/ml-injected embryos and sixteen with 5 g/ml-inject embryos. 
Eighteen Founder (“Fo') animals were produced that carried at least 
one construct. Eight Fo mice were mated with control mice which 
resulted in five lines transmitting the transgene. First generation 
offspring (“F1') from lines 1, 23 and 85 have been bred and litters 
produced. 
1.2 Lig/ml 5 g/ml 
Transfers: 14 16 
Pups alive: 68 69 
Embryos injected: 696 1098 
Embryos transferred: 480 675 
Embryos per transferred: 34.2 42.1 
Pups per litter 6.2 5.3 
Transfers pregnant: 11 13 
Pregnancy rate: 78% 81% 
Mice tested: 68 69 
Number transgenic: 7 11 
Percent transgenic: 10% 15% 
% Positive for C, B, Y: 85% 729% 
C., f, Y Transgenic females: 3 3 
TABLE 3 
10 
15 
25 
16 
Positive Fibrinogen Triple Construct F1's 
1-2,1-5, 1-6, 1-11,1-12, 1-14,1-16, 1-17.1-20,23-323-4,23-12, 
109-3,109-4,109-5,109-10,109-11,112-3,112-6,112-7, 112-8 
|B-Chain Positive Mice 
23-2,23-7,23-1185-2 
All embryos were injected with the three FIB constructs at 
a total DNA concentration of 5ug/ml or about 200-300 copies 
of each construct per pl. 
A family tree of transgene passage from Fo to F1 females 
is shown FIG. 7. Males were not retained. 
EXAMPLE 4 
Transgenic Animal DNA 
DNA can be prepared from tissue of a transgenic animal of 
any species by the method exemplified below for mice. Mar 
mur, J. Mol. Biol. 3:208 (1961), incorporated by reference. 
A 5 mm piece of mouse tail was removed from young, 
potentially transgenic mice at weaning (3 weeks) age, and 
frozen in liquid nitrogen. To the frozen tissue was added 840 
ul of Lysing Solution (8 mM EDTA-0.8% SDS-0.8%2-mer 
Oligonucleotide Primers Used for PCR Detection of 
Human Fibrinogen Transgenic Mouse 
Seq. ID No. 9. Sense strand. WAP-specific 
oligonucleotides. 
Seq. ID No. 10. Antisense AC. chain detection. 
oligonucleotide. 
Seq. ID No. 11. Antisense BB chain detection. 
oligonucleotide. 
Seq. ID No. 12. Antisense GY chain detection. 
oligonucleotide. 
A Summary of the types of fibrinogen transgenic mice 
detected in founder and offspring of founder mice is given in 
Table 4. A listing of the positive FIB triple construct founders 
(Fo) and a listing off-chain positive transgenic mice are also 
given in Table 4. 
TABLE 4 
Transmission of Fibrinogen Transgenes 
Mouse No. Transmission Frequency Genes Transmitted 
1 (C., f, Y) 9/13 (69%) C., f, Y 
23 (C., B, Y) 6/12 (50%) C., f, Y (3/6); 
B only 3/6) 
109 (C, B, Y) 5/11 (45%) C., f, Y 
112 (C., f, Y) 5/8 (62%) C., f, Y (46) 
C. only (1/6) 
C., Y only (1/6) 
85 (C., B) 1/6 (16%) f only 
113 (CBY) Of8 None 
89 (C) Of6 None 
5 - CTGTGTGGCCAAGAAGGAAGTGTTG-3 
s' - GATGTCTTTCCACAACCCTTGGGC-3' 
s' - CCCGATAGCCACCTCCTCTGATG-3' 
5 - CCTGGACTTCAAAGTAGCAGCGTC-3' 
45 
50 
55 
60 
65 
captoethanol-80 ug/ml Proteinase K-1 M sodium chlorate in 
40 mM TRIS buffer pH 8.0 and 120 mM. NaCl, and the 
mixture incubated at 50° C. The mixture was then extracted 
with 250 ul of phenol/chloroform/isoamyl alcohol (25:24:1) 
for 10-15 seconds, then centrifuged for 10 minutes. The 
supernatant fluid (about 830 ul) was removed to a fresh tube, 
and a DNA clot produced by vortexing the solution with 0.6 
Vols. ofisopropanol. The mother liquor was decanted, and the 
DNA clotrinsed twice with 80% ethanol. The DNA clot was 
isolated by 5 minutes of centrifugation, aspiration of the 
Supernatant fluid, and air drying of the clot with a stream of air 
for 10 minutes. 
The DNA clot was dissolved in 250 ul of TE buffer (10 mM 
Tris.HCl, pH 7.0-1 mM EDTA, and the solution treated with 
10 ul of a RNase mixture (1 mg/ml RNAse A and 4,000 
units/ml RNAse T1) for 1 hat 37°C. This mixture was shaken 
with 50 ul of a 24:1 (v/v) solution of chloroform-isoamyl 
alcohol for 5-10 secs., centrifuged, and the supernatant fluid 
transferred to a fresh tube. 
The recovered Supernatant fluid above was mixed sequen 
tially with 25 ul of 3 M sodium acetate and 0.5 ml of 95% 
ethanol. The supernatant fluid was decanted from the precipi 
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tated DNA, and the precipitate washed with 80% ethanol. The 
purified DNA was isolated by centrifugation, air dried, then 
dissolved in 150 ul of TE. 
Essentially the same technique was used to prepare DNA 
from pigs, and the same or similar techniques can be used to 5 
prepare DNA from other animals. 
PCR reactions on DNA samples isolated from transgenic 
animal tissue samples were carried out conventionally, as 
described above. Concentrations of DNA isolates were deter 
mined by measuring the absorbency at 260 nm of 1:20 dilu 
tions of the TE solutions described above. A portion of the 
sample was then diluted into 100 ul of TE to a concentration 
of 30 ng/ul. 
10 
15 
PCR reaction mixtures (20 Il volume 
Component Volume (ul) Concentration 
HOH 2O 
10x Taq buffer 
dNTPs 
MgCl2 
Primer 1 
Primer 2 
Taq polymerase 
DNA template 
13.25 
2.5 1 
2.0 O.2 
1.5 1.5 
O.312S O.S 
O.312S O.S 
O.12S 25 
1.O 1.2 
unitsul 
ng Lil 
25 
Procedure 
Embryolysing buffer (5ul, 0.9% Nonidet P-40 and 0.9% 
Tween 20 in 20 mMTRIS buffer) was added to each PCR tube 
along with 1 ul of prepared DNA solution, and the mixture 
overlaid with 25ul of mineral oil. The tubes were placed in an 
automatic temperature cycler (Such as that manufactured by 
N.J. Research) and heated to 98°C. for 2 minutes; the tem 
perature was then brought down to 85°C. 
PCR reaction mixture (20 ul) was added to each tube and 
40 cycles of the following protocol carried out: 
Denaturation at 96° C. for 20 seconds 
Annealing at 55° C. for 1 minute 
Elongation at 75° C. for 30 seconds 
PCR reaction products were analyzed by running 20% of 
the reaction mixture products on agarose gels and identifying 
fragment sizes by comparison with marker DNA fragments. 45 
30 
35 
40 
FIG. 7 shows that a variety of founder animals having A+ 
and/or B+ and/or G+ constructs can transmit all three or some 
of the A+, B+, and G+ transgenes. All animals were produced 
from embryos having coinjections of the same DNA solution 
containing all of the A+, B+, and G+ constructs. Detection of 50 
A+, B+ and G+ DNAs was done by PCR as described above. 
Founder animals 1, 23, 109 and 112 had all three transgenes. 
Founder animal 85 had only. A+ and B+. These founder 
animals were outbred with control (nontransgenic) mice. 
Animals 1 and 109 passed all three transgenes to 5 of 13 and 55 
5 of 11 offspring, respectively, which is typical of Mendelian 
genomic transmission for a single allele. Founder animals 23 
and 112 transmitted some transgene to 6 of 12 and 7 of 8 
animals, respectively. Several offspring of animal 23 had only 
B+, while one offspring of animal 112 had only A+ and 60 
another had A+ and G+. Thus, founder animals 23 and 112 are 
examples of triple transgenic animals having a confirmed 
separate B+ allele in the case of animal 23 and having a 
separate A+ and B+ allele in the case of animal 112. Founder 
animal 85 is also an example of a mouse with a B+ only allele. 65 
Thus, crossbreeding of animals having separate alleles and 
therefore loci for each gene can be done in order to increase 
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expression (the control over a rate limited B+ chain may be 
overcome by having a B+ allele with a more inducible loci). 
Furthermore, double and triple heterozygotes of the same 
gene (either A+ and/or B+ and/or G+) can be achieved to 
boost production levels (i.e., produce a A+B+G+, B+ animal 
by crossbreeding a B+ animal, and further crossbreeding that 
A+B+G+B+ animal with a different B+ line to obtain A+B+ 
G+.B+B+). 
EXAMPLE 5 
Transgenic Pigs 
Embryos were recovered from the oviduct. They were 
placed into a 1.5 ml microfuge tube containing approximately 
0.5 ml embryo transfer media (phosphate buffered saline 
+10% fetal calf serum, Gibco BRL). These were then centri 
fuged for 12 minutes at 16,000xg RCF (13.450 RPM) in a 
microcentrifuge (Allied Instruments, model 235C). Embryos 
were removed from the microfuge tube with a drawn and 
polished Pasteur pipette and placed into a 35mm petridish for 
examination. If the cytoplasm was still opaque with lipid Such 
that pronuclei were not visible, the embryos were centrifuged 
again for 15 minutes. Embryos to be microinjected were 
placed into a microdrop of media (approximately 100 ul) in 
the center of the lid of a 100 mm petri dish. Silicone oil was 
used to cover the microdrop and fill the lid to prevent media 
from evaporating. The petri dish lid containing the embryos 
was set onto an inverted microscope (Carl Zeiss) equipped 
with both a heated stage and Hoffman Modulation Contrast 
optics (200x final magnification). A finely drawn (Kopf Ver 
tical Pipette Puller, model 720) and polished (Narishige 
microforge, model MF-35) micropipette was used to stabilize 
the embryos while about 1-2 picoliters of HPLC-purified 
DNA solution containing approximately 200-500 copies of 
DNA construct was delivered into the male pronucleus with 
another finely drawn micropipette. Embryos surviving the 
microinjection process as judged by morphological observa 
tion were loaded into a polypropylene tube (2 mm ID) for 
transfer into the recipient pig. Seven Surgical transfers of pig 
embryos were made. These embryos had been coinjected 
with the WAP-fibrinogen cINA constructs used in the above 
mentioned transgenic fibrinogen mice only one of these 
recipient gilts was confirmed pregnant by ultrasound. The 
(apparent) non-pregnant animals were kept to tentative term 
as their (potential) litter sizes may have been too small to 
detect by ultrasound analysis (In the past, three litters of four 
piglets or fewer were not detected by ultrasound. Some of 
these litters produced transgenic animals.) 
TABLE 5 
Fibrinogen Porcine Embryo Data 
Transfer Totals 
Expt. 1 Expt. 2 Oct. 25, 1993 ID 
Number of donors: 8 8 Transfer #1 
50 embryos #129 
Number of 261 283 Transfer #2 
ovulations: 47 embryos #147 
Embryos collected: 250 296 Transfer #3 
44 embryos #108 
Number of UFOs: 99 77 
UFO's that cleaved: 29 6 
Number injected: 141 219 10:28 
Number transferred: 141 2OO Transfer #1 
50 embryos #114 
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TABLE 5-continued 
Fibrinogen Porcine Embryo Data 
Transfer Totals 
Expt. 1 Expt. 2 Oct. 25, 1993 ID 
Transfers: 3 4 Transfer #2 
50 embryos #139 
Embryos Transfer: 47 50 Transfer #3 
50 embryos i140 
Ovulations/Pig: 32.6 35.3 Transfer #4 
50 embryos #131 
Embryos Pig: 31.2 37 
All embryos were injected with the three fibrinogen con 
structs at a total DNA concentration of 5 g/ml or about 
200-300 copies of each construct per pl. 
EXAMPLE 6 
Preparation of Milk and Whey from Transgenic 
Animals 
Lactating mice were milked once on about day 12 of lac 
tation. The mice were first separated from their young for 
approximately 5 hours. They were then anesthetized with 0.4 
ml avertin at 2.5% (im.), and 0.2 ml oxytocin was then admin 
istered at 2.5 IU/ml (i.p.) to permit release of the milk. A 
milking device consisting of a vacuum pump (2.5 psi) and 
Syringe with an Eppendorf tip was used to direct milk into an 
eppendorf tube. As noted above, milk should not be placed on 
ice because of cryoprecipitation of fibrinogen. 
To prepare whey, milk was diluted 1:1 with TRIS buffer 
(0.03 M Tris pH 7.4; 0.06 M NaCl) and centrifuged in a 
TLA-100 rotor in a Beckman TL-100 table top ultracentri 
fuge at 51,000 rpm (89.000xg) for 30 minutes at room tem 
perature. After centrifugation, the whey (infranatant fluid) 
was collected with an 18 gauge needle, leaving the casein 
pellet and upper cream layer in the tube. To remove solids or 
cream that co-transferred during the initial recovery, the whey 
obtained from the first centrifugation was subjected to a sec 
ond spin at 12,000 rpm for 30 minutes in a TMA-4 rotor in a 
Tomy MTX-150 centrifuge. Following the second spin, the 
whey was recovered as before. 
EXAMPLE 7 
Determination of Fibrinogen in Milk by a Sandwich 
ELISA 
A sandwich ELISA was used to measure the amount of FIB 
protein produced by founder and progenic transgenic animals 
in the diluted skim or defatted milk (here termed “whey'); the 
whey value is used to estimate the concentration of FIB in 
whole milk. 
Generally, in the first step of the P/M ELISA system, a 
fibrinogen or fibrinogen chain analyte-containing sample (for 
example, whey) is incubated with a mouse anti-human 
fibrinogen mAb (clonal number 311, American Diagnostics) 
that is reactive with the alpha chain of fibrinogen to form a 
mAb-fibrinogen (or chain) first complex. This first complex is 
then “captured by incubation with rabbit polyclonal anti 
human fibrinogen antibodies immobilized in microliter plate 
wells. In the detection step, the captured fibrinogen (or alpha 
chains) is contacted with labeled (horse radish peroxidase) 
anti-mouse IgG, and the amount of label quantified by reac 
10 
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tion with o-phenylenediamine and measurement of absor 
bency at 490 nmi; this is a measure of the amount of analyte 
present. Standard curves were obtained by spiking the whey 
of control (nontransgenic) animals with pure reference 
human FIB material. Thus, the presence of background 
amounts of FIB is normalized by the standard curve. This 
sandwich ELISA gives very low background values (about 
0.06 absorbency units at 490 nm) for mouse whey alone with 
no human FIB. Note the typical signals given in Table 6 are 
about 0.25 or higher absorbency units at this wavelength. 
In the P/P system, Immulon II 96-well microliter plates 
were coated with 100 pul?well of 1:500 diluted rabbit anti 
human FIB (Celsus cat. no. 60960) in 0.1 M NaHCO-0.1 M 
NaCl, pH 9.6, for 24 hours at refrigerator temperatures. 
Coated wells were washed three times with Wash Buffer (25 
mM Tris-HC1-50 mM. NaCl-0.5% Tween-20, pH 7.0) and 
blocked for 20 minutes with Dilution Buffer (1 mg/ml PEG in 
25 mM Tris-HC1-50 mMNaCl, pH 7.0) at room temperature. 
A volume of 100 ul of standard human FIB (100 ng/ml to 1.9 
ng/ml range) and/or 100 ul of diluted milk sample was added 
to each well, and the mixtures incubated at 37° C. for 45 
minutes. The wells were washed and blocked as above for 10 
minutes at room temperature. 100 ul of 1:1000 diluted horse 
radish peroxide-conjugated rabbit anti-human FIB were 
added to each well, and the mixtures incubated at 37° C. for 
45 minutes. After washing the wells as above, 100 ul of 
o-phenylenediamine solution (1 tablet/5 ml diluent) were 
added to each well. After waiting about 2-3 minutes for color 
development, reactions were stopped by the addition to each 
well of 100 ul of 3 NHSO. Plates were then read at 490 nm. 
Table 6 presents the results of the analyses of rhFIB by the 
P/M ELISA system described above in the first lactation 
whey (and in whole milk by calculation) of three founder (Fo) 
transgenic mice whose genome contained each of the AC, Bf3, 
and GY chains cloNAs for human fibrinogen. In this experi 
ment, “whey refers to skim milk diluted 1.7x with EDTA to 
solubilize the caseins. The averages of four dilutions of each 
whey sample for the three test animals was about 16.3, 3.86 
and 7.55 ug/ml, respectively. The corresponding values for 
whole milk were 27.6, 6.56 and 12.8. Second lactation pro 
duction of rhEIB was similar. 
In another experiment with the same animals the first lac 
tation whey fibrinogen concentrations averaged about 22-4 
(animal 1), 9+2 (animal 22) and 11+3 (animal 23) ug/ml. The 
second lactation of animal 1 produced 17t3 ug/ml whey. 
The P/M ELISA system was used to assay for rhFIB in the 
third lactation milk of mouse no. 1/Fo and the first lactation of 
mouse no. 1 female offspring (1-11/F1). As shown in the data 
of Table 7, mouse no. 1/Fo had about 71 ug/ml, and her 
offspring (no. 1-1 1/F1) had about 53 g/ml total FIB signal. 
Thus, the amount of rFIB after subtracting background is 
calculated to be about 50 ug/ml for mouse no. 1/Fo and about 
32 ug/ml for offspring 1-1 1/F1, respectively, over that of 
endogenous FIB present from serum to milk passover. The 
slightly lower value (28 ug/ml) of the P/Massay of the pre 
vious lactation of mouse no. 1/Fo is not significantly different 
than the P/P value when lower detection sensitivity of the 
former method is taken into account. It is noted that collection 
of mouse milk is inherently traumatic and, leads to serum 
passover of endogenous mFIB. 
In summary, mouse no. 1/Fo (founder) produced rEIB in 
milkata level of about 30 ug/ml or greater over 3 lactations as 
detected by either the P/M or P/P ELISA methods, and has 
passed this trait on into the F1 generation which, in mouse no. 
1-1 1/F1, produced 32 g/ml rFIB. 
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TABLE 7 
Inheritability of Transgenic rhEIB Gene 
Mouse No. diluted whey grhFIB/ml milk 
1 Fo 14.O 2.0 71.O 
1-11 F1 10.4 0.8 53.0 
Control whey 4.O. O.7 21.O 
10 
These productions are Substantially greater than the 2 
ug/ml produced in the COS1 system described by Roy et al., 
1991, above. 
Western analysis of control mouse milk using polyclonal 15 
anti-human fibrinogen antibody showed about 21 ug/ml of 
background fibrinogen signal (see Table 7). Western analysis 
that uses the clonal number 311 or Y18 monoclonal antibody 
has a lower limit of sensitivity of about 1 ul sample of 100 
ug/ml fibrinogen (Phastgel system) or 20 Jul of 25 g/ml in a 
3" by 4" SDS-PAGE gel. 
TABLE 6 
C 
A. B AVGABS E WHEY 
1 Animal Dilutions 490 mm D FIBug?ml AVG FIBug?ml 
2 #1 DAY 6 100 O.623 O.132 13.2 
3 2OO O.S23 O.088 17.6 16.3 
4 400 O434 0.049 19.4 
5 800 O.334 0.018 14.7 
6 
7 H22 1OO O.374 O.O22 2.16 
8 2OO O.335 0.018, 3.69 3.86 
9 400 O.273 0.014 S.73 
10 800 O.251 O.O13 10.3 
11 
12 #23 1OO O.477 0.067 6.75 
13 2OO O.384 O.O26 S.22 7.55 
14 400 O.338 0.019 7.44 
15 800 O.261 O.O13 10.8 
EXAMPLE 8 
Confirmation that Transgenic Fibrinogen is Actually 
Recombinant Human Fibrinogen 
Materials Used to Analyze Fibrinogen 
Rabbit antisera against human fibrinogen was purchased 
from Celsus laboratories (Cincinnati, Ohio). Rabbit antisera 
against human fibrinogen conjugated to horseradish peroxi 
dase (HRP) was purchased from Dako corporation (Carpen 
teria, Calif.). Anti-rabbit immunoglobulins conjugated to 
HRP were purchased from Sigma Chemical Company 
(St.Louis, Mo.). Synthetic human fibrinopeptide A was pur 
chased from Sigma Chemical Company. Rabbit antisera 
against human fibrinopeptide A was purchased from Nordic 
Immunological Laboratories (Caplstrano Beach, Calif.). 
Immulon II microtiter plates were purchased from Fisher 
Scientific (Pittsburgh, Pa.). Plasma derived human fibrinogen 
was provided by American Red Cross. (Rockville, Md.). 
O-phenylenediamine-2HCl (OPD) tablets were purchased 
from Abbott Laboratories (Chicago, Ill.). Metal enhanced 
DAB substrate was purchased from Pierce Chemical Com 
pany (Rockford, Ill.). Centricon diafilters were purchased 
from Amicon (Bedford, Mass.). 4-15% gradient phast-gels 
were purchased from Pharmacia Biotech (Piscataway, N.J.). 
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Nitrocellulose papers (40 microns pore size) were purchased 
from Sigma Chemical Company. DEAE-Fast flow sepharose 
was purchased from Pharmacia Biotech (Piscataway, N.J.). 
DEAE chromatography was performed with Pharmacia C-10 
columns (15 cmx1 cm), a Masterflex peristaltic pump, a 
Knauer spectrophotometer, and a Rainin data acquisition sys 
tem were used to monitor chromatography. All other reagents 
were purchased from Sigma Chemical Company at the best 
grade available. Columns were kept at 4°C. with a Lauda 
Super RMT water cooler. 
A. Separation of Transgenic Human FIB from Host Mouse 
FIB 
A sequence of anion exchange adsorption to reduce back 
ground protein content followed by a 2-step Zinc ion-selective 
separation of hFIB or rhFIB from mouse FIB was done on 
mouse milk whey and mouse plasma samples (FIG. 8). Milk 
from transgenic and non-injected control mice were diluted 
with an equal volume of 200 mM EDTA, pH 7.0. An aliquot 
of milk from control (nontransgenic mice) was spiked with 
known hFIB to give a final concentration of 30-50 ug/ml, and 
27.6 
6.56 
12.8 
diluted with 1 part EDTA. The milk: EDTA mixture was cen 
trifuged at 4400 rpm for 45 minutes and the whey phase was 
separated from the top fat layer. Mouse blood was used as a 
positive control to measure cross-reactivity of anti-human 
fibrinogen antisera to mouse fibrinogen. All samples were 
diafiltered against TBS (25 mM Tris-HCl, 100 mM. NaCl, pH 
7.0) and then were fractionated on a DEAE Fast Flow 
Sepharose packed column at a linear Velocity of 1 cm/min. 
The column dimensions were: 1 cm bed diameter and 6 cm in 
length. A fraction obtained by elution with 0.2 MNaCl frac 
tion was diafiltered against TBS and reconstituted to the 
original sample Volume. Using a 0.5 MZnCl2 stock solution, 
the Zinc ion concentration in the samples was adjusted to 10 
mM. This gave a visible precipitate which was separated by 
centrifugation at 10000 rpm (rotor diameter 6 inches) for 20 
mins (pellet 1). Pellet-1 was dissolved in 100 mM EDTA, pH 
7.0. Using the stock Solution, the Zinc concentration in the 
supernatant fluid was adjusted to 24 mM. The resultant pre 
cipitate was centrifuged at 10000 rpm for 10 mins and the 
sediment (pellet-2) was dissolved in 100 mM EDTA, pH 7.0. 
EDTA solutions from pellet-1 and pellet-2, as well as associ 
ated-supernatant fluids, were analyzed for rhFIB by ELISA 
and the fractions were diafiltered against TBS. 
Pellets from control mouse whey alone (no doped human 
fibrinogen) were dissolved to the same dilution factor as 
pellets from transgenic whey and human fibrinogen doped 
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control whey. ELISA values for the dissolved transgenic 
whey and human fibrinogen doped control whey were 30-50 
ug/ml human fibrinogen. The control (pellet-2) when recon 
stituted to the same volume as TG (pellet-2) or hFIB spiked 
control whey (pellet-2) gave a fibrinogen level of 1-2 g/ml as 5 
measured by ELISA. 
The pellet-2 of non-transgenic whey was also reconstituted 
to a 20-fold more-concentrated level than transgenic whey 
and human fibrinogen doped control whey. This 20-fold con 
centrated, negative control was assayed by ELISA, and the 
value was then 30 g/ml human fibrinogen cross reactive 
equivalent signal with human fibrinogen antisera. 
The dissolved pellets from transgenic whey and human 
fibrinogen doped control whey having 30-50 ug/ml human 
fibrinogen by ELISA signal were applied to a phast-gel, SDS- 15 
PAGE (1 Jul sample Volume applied to phastgel). A 1 Jul appli 
cation of the 20 fold-more concentrated, negative-control, 
dissolved pellet also was applied to the gel. 
B. Western Blot Analysis Under Non-Reducing Conditions 
hFIB (reference) in assay buffer, diafiltered mouse plasma 
and rhFIB- rich fraction (pellet-2 of zinc separation step) of 
transgenic whey were mixed with non-reducing cocktail at 
4:1 ratio and boiled for 5 minutes. Samples were analyzed on 
a 4-15% SDS-phast gel. Upon the completion of electro 
phoretic separation, the proteins were blotted onto a nitrocel 
lulose membrane via “phast-gel diffusion blotting.” The blot 
was probed for hFIB or rhFIB by a sandwich of rabbit anti 
human fibrinogen antibody and anti-rabbit HRP conjugate 
antibody. Bound chromophore was visualized by metal 
enhanced DAB substrate. The results are shown in FIG. 9. 
Lanes 1 and 8 of FIG. 9 show applications of hFIB refer 
ence protein at 100 and 10 ngs. Lanes 2 and 3 shows the 
transgenic pellet from mouse (1-11-8) at 15 ngs. Lanes 4 and 
show the transgenic pellet from mouse 1-6-8 at 30 ngs. Lane 
6 shows mouse plasma derivative at 2-4 ug of total protein 
application. Lane 8 shows pellet-2 from control whey. 
The mobilities of rhFIBs under non-reducing conditions on 
4-15% PAGE phast-gel from two different transgenic mice 
lines are similar to that of the plasma-derived hFIB reference 
(lanes 2-5). Intact mouse FIB from plasma (lane 6) and con 
trol whey pellet-2 (lane 7) migrated as multiple bands with a 
distinctly apparent higher molecular weight as compared to 
human FIB (lanes 1 and 10). 
C. Western Blot Analysis Under Reducing Conditions 
hFIB (reference protein) in assay buffer, diafiltered mouse 
plasma and rhFIB-rich fraction (pellet-2 of zinc separation 
step) of transgenic whey were mixed with reducing cocktail at 
4:1 ratio and boiled for 5 minutes. Samples were analyzed on 
a 8-25% SDS-phast gel. Upon the completion of electro 
phoretic separation, the proteins were blotted onto a nitrocel 
lulose membrane via “phast-gel diffusion blotting.” The blot 
was probed for hFIB or rhFIB by a sandwich of rabbit anti 
human FIB and anti-rabbit HRP conjugate antibodies. Bound 
chromophore was visualized by metal-enhanced DAB sub 
strate. The results are shown in FIG. 10. 
Lanes 1, 2 and 3 of FIG. 10 show applications of hFIB 
reference at 100, 50-and 10 ngs. Lane 4 shows mouse plasma 
derivative (i.e. diafiltered 0.2. MNaCl eluate from DEAE FF 
Sepharose column). Lane 5, 6, 7 and 8 show applications of 
transgenic whey pellet-2 at 60, 30, 15 and 7.5 ngs. 
Under reduced conditions, C, B and Y chains of reference 
hFIB from human plasma are clearly visible (lanes 1-3). 
Fibrinogen chains from mouse plasma (lane 4) have lower 
apparent molecular weights than human FIB, but different 
than rhEIB. Partially purified material from transgenic whey 
has three chains with lower apparent molecular weights than 
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hFIB (lanes 5-8), but a higher molecular weight than mouse 
fibrinogen. The C.B chains of rhFIB show up with greater 
intensity than the Y chain. 
D. Thrombin Assay 
Diafiltered rhEIB-rich fractions from the zinc selective 
separation steps were suspended in 50 mM imidazole, 150 
mM NaCl, 30 mM CaCl, pH 8.0. Human thrombin was 
added to a final concentration of 4U/ml and the samples were 
incubated at 37°C. for 24 hours. Cloudy clot-like precipitates 
were clearly visible in TG (pellet-2), hFIB-spiked NTG (pel 
let-2), but not in control whey (pellet-2) after treated with 
thrombin. The clots were boiled for 3 mins and centrifuged at 
10000 rpm for 10 minutes. The clot pellets were dissolved in 
reducing cocktail buffer. Assay Supernatant was lyophilized 
and reconstituted to /1oth the initial reaction volume. Super 
natant was assayed for any residual fibrinogen and/or fibrin 
by ELISA. The level of FPA in the concentrated supernatants 
were determined by EIA technique. 
E. Western Blot Analysis. After Treatment of FIBs with 
Human Thrombin 
Samples were taken before the addition of thrombin 
(Time=0 mins) and the clot after polymerization were dis 
solved in reducing buffer. Samples were analyzed on a 8-25% 
phast gel in the presence of SDS. The results are shown in 
FIG 11. 
Lanes 1 and 2 of FIG. 11 show human fibrinogen reference 
protein in buffer at concentrations of 50 and 10 ngs before the 
addition of thrombin. Lane 3 shows the dissolved clot gener 
ated from hFIB at an initial concentration of 10 ng. Lane 4 
shows trangenic whey pellet-2 FIB (30 ng applied to gel) 
before addition of thrombin. Lane 5 shows dissolved clot 
generated from transgenic whey pellet-2 FIB. Lane 6 shows 
mouse plasma derivative (30ng total FIB cross reactive signal 
by ELISA, 1000 ng mouse FIB by silver-stain analysis using 
SDS-PAGE). Lane 7 shows samples from the incubation of 
mouse plasma derivative FIB with thrombin; this precipitate 
is not the cloudy gel-like precipitate seen with TG whey 
(pellet-2) and hFIB spiked control whey (pellet-2). 
The Western analysis under reducing conditions of the 
hFIB reference protein shows three distinct chains, and the 
dissolved clot resulting from thrombindigestion shows three 
chains with an apparent lower molecular mobility under 
reduced conditions. Release of fibrinopeptide A from the a 
chain by incubation with thrombin results in a lower apparent 
molecular of the a chain. Dissolved clots from transgenic 
whey (pellet-2) under reducing conditions gave two distinct 
bands with lower apparent molecular weights when com 
pared to rhFIB before addition of thrombin. A mouse plasma 
sample gave bands which were reactive to FIB antisera and 
had lower apparent molecular weights than reduced hFIB. 
F. Assay of Fibrinopeptide A After Thrombin Digestion of 
rhEIB 
The levels of FPA in the concentrated samples were deter 
mined by an EIA technique. Immobilon AV membranes were 
wetted in imidazole buffer for 10 minutes and dried for 60-90 
minutes at room temperature. FPA standards ranging from 
0.2-0.125 mg/ml and assay Supernatant fluids were applied as 
1 ul spots onto a pre-wetted Immobilon AV membrane for the 
purpose of covalent immobilization. Smaller peptides such as 
FPA (MW 1,800) are kinetically favored for immobilization 
over larger peptides or milk proteins with molecular weights 
in excess of 10,000. The spots were allowed to dry at room 
temperature and the membrane was blocked with 0.5% casein 
for 2 hours at the same temperature. Covalently bound FPA 
was detected with a sandwich of rabbit anti-FPA and anti 
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rabbit/HRP conjugate antibodies. Bound chromophore was 
detected with metal enhanced DAB substrate. The spots were 
scanned on a Shimazdu Densitometer at 270 nm. The results 
are summarized in Table 8. 
FPA standards ranging from 200-6.25 ngs were applied to 
enzyme immunoassay (EIA) membranes for reference signal 
curves. Transgenic whey derivatives that had been selectively 
enriched for recombinant human fibrinogen by precipitation, 
were similarly applied and analyzed for the release of FPA 
before and after human thrombin treatment for 24 hours. 
Analogously prepared and then thrombin treated, non-trans 
genic whey derivatives were also compared in the same EIA 
assay. These results are summarized in Table 8 entitled 
“Thrombin treatment of Fibrinogen Samples'. 
The yield of FPA from hFIB in assay buffer treated with 
thrombin was 100+10% based on three independent trials 
(Table 8). No detectable amount of FPA was released from 
control whey (pellet-2) treated with thrombin. 1,000 ng of 
mouse FIB from mouse plasma (equivalent to 25 ngs of FIB 
cross reactive signal) gave a FPA yield of 5%. Transgenic 
whey (pellet-2) and hFIB spiked control whey (pellet-2) 
when treated with thrombin released FPA in the supernatant 
fluid, and no residual rhEIB or hEIB was detected in the 
supernatant fluid by ELISA. The yield based on the amount of 
FPA released from TG whey (pellet-2) and hEIB spiked con 
trol whey (pellet-2) is estimated to be 60+8% and 75+9%. 
respectively based on three independent trials. A 1/1 molar 
ratio of FPA to fibrinogen is assumed in the calculation. 
TABLE 8 
Thrombin Treatment of Fibrinogen Samples 
Fibrinogen giml % FPA 
ELISA yield 
Sample T = O T = 24 T = 24 
(Supernatant) min hours hours 
hFIB (buffer) 100 O.1 1OO 5 
hFIB (buffer) 10 n.d. 1OO 10 
Spiked NTG whey 50 O.1 7S 9 
(pellet-2) 
TG whey (pellet-2) 30 n.d. 608 
NTG whey (pellet-2) 30 n.d. n.d. 
Mouse plasma 30 n.d. 5 
G. Summary 
Mouse FIB was found to have a higher apparent molecular 
weight under nonreducing conditions both by silver-stained 
SDS-PAGE gels and corresponding Western blot analyses 
using polyclonal anti-human fibrinogen antisera, than human 
FIB. In contrast, the separate C, B and Y chains of the mouse 
plasma FIB, as detected by gel analyses under reducing con 
ditions, had slightly lower apparent molecular weights (about 
1-5 kDa per chain) than human FIB. These data from reduced 
and nonreduced analyses indicate that the disulfide bridging 
and resultant SDS-sensitive conformation of the assembled 
mouse FIB is different than for the human counterpart. Fur 
thermore, the cross-reactivity to anti-human fibrinogen signal 
was about 40-fold less than human or rhEIB in both ELISA 
and Western analysis assuming about 2 g/l mouse FIB in 
mouse plasma reference as detected by silver stain gel. Mouse 
plasma FIB was, also found in transgenic and control mouse 
milks at about 200 to 300 g/ml. After purification process 
ing, all Zn-derived pellet-2 from nondoped control whey or 
mouse, plasmas exhibited no detectable clot formation nor 
FPA formation after treatment with human thrombin. But 
lower apparent molecular weight FIB chain reaction products 
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may have been produced by treatment with thrombin under 
conditions of about 20-fold higher initial concentration of 
FIB substrate than used for human FIB-doped whey deriva 
tive or rhFIB samples. Both the absence of FPA and an obvi 
ous clot after treatment with human thrombin was expected. 
While mouse FIBundoubtedly has regions of well-conserved 
sequence homology, both the mouse FPA sequence and the 
nature of the digestion by human thrombin (slower reaction 
kinetics due to site specificity of human thrombin for human 
fibrinogen) is likely to be different. The 40-fold lower cross 
reactivity of mouse FIB with anti-hFIB antisera is additional 
evidence of the differences in mouse and human fibrinogens. 
The FIB doped into whey and recovered by the above 
purification process was readily converted to fibrin by the 
addition of human thrombin. A normal fibrin clot and sto 
ichiometric release of FPA into the supernatant solution was 
found after treatment with thrombin. A characteristically 
lower apparent molecular weight of the fibrin chains from the 
clot was found relative to the starting FIB precursor chains. 
The assembled rhFIB possessed an apparent molecular 
weight similar to that of human FIB reference standard. The 
physicochemical properties of the rhFIB were similar to those 
of hFIB as reflected by the similar partitioning during the 
Zn+ selective purification scheme. Zn4 is a coordinate 
covalent bonder of proteins primarily through access to proxi 
mally portioned, Surface positioned histidine residues, and 
thus the tertiary conformation of the proteins is changed by 
the formation of Zn-i- bonds Lonnerdal (1982), supra. 
Changes intertiary confirmation by Zn-bonding are reflected 
in a Zn-concentration dependent manner by the precipitation 
(loss of solubility). Similar amounts of recombinant and 
human FIB precipitated out at 24 mM Zn4 and as found in 
pellet-2. The sensitivity of this technique is seen with the 
structurally related mouse FIB which did not precipitate to 
any significant degree at this same level of Zn. Thus, the 
presentation of surface histidine residues is similar between 
human and recombinant FIB, but much different for mouse 
FIB. The separate chains of rhFIB will slightly lower apparent 
molecular weights than non-recombinant human FIB due 
possibly to glycosylation off and Y chains. The reactivity to 
anti-human fibrinogen antisera of purified recombinant 
fibrinogen was generally equivalent to human fibrinogen. 
The rhEIB recovered from the transgenic was readily con 
verted to fibrin by the addition of human thrombin and in a 
manner similar to that of human FIB reference protein. A 
normal human fibrin clot and stoichiometric release of FPA 
into the supernatant solution was found after treatment with 
human thrombin. The yield of FPA detected by EIA after 
treatment with human thrombin for rhFIB fibrinogen was 
equivalent to that obtained with human FIB. As the yields of 
fibrin from human or recombinant fibrinogens were high, the 
residual milk proteins present after purification did not inter 
fere significantly with the thrombin-fibrinogen reaction. A 
characteristically lower apparent molecular weight of the 
recombinant human fibrin chains from the clot was found 
relative to the starting FIB precursor chains. 
In summary, these analyses have shown that the rhFIB 
made has a genuine and native structure with respect to bio 
logical activity. This was evidenced by its simultaneous con 
Sumption and conversion into a normal fibrin clot while act 
ing as a substrate during enzymatic reaction with human 
thrombin, stoichiometric release of native fibrinopeptide A 
upon formation of fibrin, lower relative molecular weights of 
resultant fibrin polypeptide chains relative to FIB precursors, 
its coordinate chemical bonding properties with Zn, and its 
equivalent reactivity with human antisera relative to a human 
FIB reference protein. 
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SEQUENCE LISTING 
<16O NUMBER OF SEO ID NOS : 12 
<210 SEQ ID NO 1 
<211 LENGTH: 2O 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
primer 
<4 OO SEQUENCE: 1 
CCCC agctgc agc catgaag 
<210 SEQ ID NO 2 
<211 LENGTH: 28 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
primer 
<4 OO SEQUENCE: 2 
CCCC agggat at CCCtgcag C catgaag 
<210 SEQ ID NO 3 
<211 LENGTH: 30 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
primer 
<4 OO SEQUENCE: 3 
gctagg tacc atgtttitcca taggat.cgt 
<210 SEQ ID NO 4 
<211 LENGTH: 30 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
primer 
<4 OO SEQUENCE: 4 
Cagtgg tacc ctagacaggg Cagatttag 
<210 SEQ ID NO 5 
<211 LENGTH: 30 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
primer 
<4 OO SEQUENCE: 5 
gctagg tacc atgaaaagaa tigtttcgtg 
<210 SEQ ID NO 6 
<211 LENGTH: 30 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
primer 
<4 OO SEQUENCE: 6 
Synthetic 
Synthetic 
28 
Synthetic 
3 O 
Synthetic 
3 O 
Synthetic 
3 O 
Synthetic 
28 
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- Continued 
Cagtgg tacc ctattgctgt gggaagaagg 
<210 SEQ ID NO 7 
<211 LENGTH: 30 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
primer 
<4 OO SEQUENCE: 7 
gctagg tacc atgagttggit CCttgcaccc 
<210 SEQ ID NO 8 
<211 LENGTH: 30 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
primer 
<4 OO SEQUENCE: 8 
cagtgg tacc ttaaacgt.ct c cagoctdtt 
<210 SEQ ID NO 9 
<211 LENGTH: 25 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
primer 
<4 OO SEQUENCE: 9 
Ctgtgtggcc aagaaggaag tittg 
<210 SEQ ID NO 10 
<211 LENGTH: 24 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
primer 
<4 OO SEQUENCE: 10 
gatgtc.tttc. cacaac cctt gggc 
<210 SEQ ID NO 11 
<211 LENGTH: 23 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
primer 
<4 OO SEQUENCE: 11 
cc.cgatagcc acct cotctg atg 
<210 SEQ ID NO 12 
<211 LENGTH: 24 
&212> TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
&220s FEATURE: 
<223> OTHER INFORMATION: Description of Artificial Sequence: 
primer 
3 O 
Synthetic 
3 O 
Synthetic 
3 O 
Synthetic 
25 
Synthetic 
24 
Synthetic 
23 
Synthetic 
30 
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- Continued 
<4 OO SEQUENCE: 12 
Cctggactitc aaagtagcag cqtc 
What is claimed is: 
1. A method for producing biologically active fibrin com 
prising: 
providing a transgenic non-human mammal whose 
genome comprises a first DNA segment encoding a het 
erologous fibrinogen AC chain, a second DNA segment 
encoding a heterologous fibrinogen Bf3 chain, and a third 
DNA segment encoding a heterologous fibrinogen Gy 
chain, wherein each of said first, second and third seg 
ments is operably linked to a cis-acting, expression pro 
moter-containing regulatory sequence; 
allowing the expression of said first, second and third DNA 
segments in said mammal and the production of milk 
containing said biologically active fibrinogen; 
collecting milk from said mammal; 
recovering the fibrinogen from said milk, and 
converting the fibrinogen to fibrin by reacting the fibrino 
gen with thrombin. 
2. The method of claim 1, wherein said conversion of 
fibrinogen to fibrin occurs in a Subject which has been admin 
istered said fibrinogen. 
3. A method for producing biologically active fibrin com 
prising: 
providing a transgenic non-human mammal whose 
genome comprises a first DNA segment encoding a het 
erologous fibrinogen AC chain, a second DNA segment 
encoding a heterologous fibrinogen Bf3 chain, and a third 
DNA segment encoding a heterologous fibrinogen Gy 
chain, wherein each of said first, second and third seg 
ments is operably linked to a cis-acting, expression pro 
moter-containing regulatory sequence; 
allowing the expression of said first, second and third DNA 
segments in said mammal and the production of milk 
containing biologically active fibrinogen; 
collecting milk from said mammal; 
recovering the fibrinogen from said milk, and 
converting the fibrinogen to fibrin by reacting the fibrino 
gen with at least one protease. 
4. The method of claim 3, wherein said conversion of 
fibrinogen to fibrin occurs in a Subject which has been admin 
istered said fibrinogen. 
5. A method for producing biologically active fibrin com 
prising: 
recovering fibrinogen from the milk of a transgenic non 
human mammal whose genome comprises a first DNA 
segment encoding a heterologous fibrinogenAC chain, a 
second DNA segment encoding a heterologous fibrino 
gen Bf3 chain, and a third DNA segment encoding a 
heterologous fibrinogen GY chain, wherein each of said 
first, second and third segments is operably linked to a 
cis-acting, expression promoter-containing regulatory 
sequence which allows the expression of said first, sec 
ond and third DNA segments in said mammal; and 
converting the fibrinogen to fibrin by reacting the fibrino 
gen with at least one protease. 
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6. The method of claim 5, wherein said protease is throm 
bin. 
7. The method of claim 6, wherein said conversion of 
fibrinogen to fibrin occurs in a Subject which has been admin 
istered said fibrinogen. 
8. A method for producing biologically active fibrinogen 
comprising: 
providing a female transgenic non-human mammal com 
prising stably integrated in its genome a first DNA seg 
ment encoding a first DNA segment encoding a heter 
ologous fibrinogen AC chain, a second DNA segment 
encoding a second DNA encoding a heterologous 
fibrinogen Bf3 chain, and a third DNA segment encoding 
a third DNA encoding a heterologous fibrinogen Gy 
chain, wherein each chain is derived from the same 
species, and wherein each of said first, second and third 
segments is operably linked to a promoter-containing 
regulatory sequence required for its expression in a 
mammary gland of a transgenic non-human mammal; 
allowing the expression of said first, second and third DNA 
segments and the assembly of the expressed individual 
AC, BB and GY polypeptides into biologically active 
fibrinogen in the cells of the mammary gland followed 
by the secretion of the biologically active fibrinogen into 
the milk of said female mammal; 
collecting milk from said mammal; and 
recovering the biologically active fibrinogen from the milk 
in concentrations of 30 ug/ml or greater. 
9. The method according to claim 8, wherein said trans 
genic non-human mammal is selected from the group con 
sisting of a rodent, rabbit, sheep, pig, goat and cattle. 
10. The method according to claim 8, wherein said pro 
moter is a mammary gland specific promoter. 
11. The method according to claim 10, wherein said pro 
moter is selected from the group consisting of casein, 3-lac 
toglobulin, C.-lactalbumin and whey acidic protein gene pro 
moters. 
12. The method according to claim8, wherein said fibrino 
gen is human fibrinogen. 
13. The method according to claim 8, wherein said first, 
second, and third DNA segments further comprises an intron. 
14. A method for producing biologically active fibrinogen 
comprising: 
providing a first DNA segment encoding a heterologous 
fibrinogen AC chain, a second DNA segment encoding a 
heterologous fibrinogen Bf3 chain; and a third DNA seg 
ment encoding a heterologous fibrinogen GY chain, 
wherein each chain is from the same species, and 
wherein each of said first, second and third segments is 
operably linked to a promoter-containing regulatory 
sequence required for its expression in the mammary 
gland of a female transgenic non-human mammal; 
introducing said DNA segments into a fertilized egg of a 
non-human mammalian species heterologous to the spe 
cies of origin of said fibrinogen chains; 
US 7,435,869 B2 
33 
inserting said egg into an Oviduct or uterus of a female of 
said mammalian species to obtain a transgenic non 
human mammal whose genome comprises said DNA 
Segments; 
breeding said mammal to produce female progeny that 
express said first, second and third DNA segments, 
wherein the assembly of the expressed individual AC. 
BB and Gypolypeptides into biologically active fibrino 
gen occurs in the cells of the mammary gland followed 
by the secretion of the biologically active fibrinogen into 
the milk of said female mammal; 
collecting milk from said female progeny; and 
recovering the biologically active fibrinogen from the milk 
in concentrations of 30 ug/ml or greater. 
15. The method according to claim 14, wherein said trans 
genic non-human mammal is selected from the group con 
sisting of a rodent, rabbit, sheep, pig, goat and cattle. 
16. The method according to claim 14, wherein said first, 
second, and third DNA segments further comprises an intron. 
17. The method according to claim 14, wherein said pro 
moter is a mammary gland specific promoter. 
18. The method according to claim 17, wherein said pro 
moter is selected from the group consisting of casein, 3-lac 
toglobulin, C.-lactalbumin and whey acidic protein gene pro 
moters. 
19. The method according to claim 14, wherein said 
fibrinogen is human fibrinogen. 
20. A transgenic non-human mammal, wherein the genome 
of said mammal comprises: 
a first DNA segment encoding a heterologous fibrinogen 
AC. chain; 
a second DNA segment encoding a heterologous fibrino 
gen Bf3 chain; and 
a third DNA segment encoding a heterologous fibrinogen 
GY chain; and 
wherein each chain is derived from the same species and is 
operably linked to a promoter-containing regulatory 
sequence required for its expression in the mammary 
gland of a host mammal, and wherein expression of said 
DNA segments and the assembly of the expressed indi 
vidual AC, BB and Gy polypeptides into biologically 
active fibrinogen occurs in the cells of the mammary 
gland followed by the secretion of the biologically active 
fibrinogen into the milk, if said mammal is female, 
resulting in the production of recoverable quantities of 
biologically active fibrinogen from milk of said non 
human mammal in concentrations of 30 ug/ml or greater. 
21. The non-human transgenic mammal according to claim 
20, wherein said non-human mammal is selected from the 
group consisting of a rodent, rabbit, sheep, pig, goat and 
cattle. 
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22. The method according to claim 20, wherein said pro 
moter is a mammary gland specific promoter. 
23. The non-human transgenic mammal according to claim 
22, wherein said promoter is selected from the group consist 
ing of casein, B-lactoglobulin, C.-lactalbuminand whey acidic 
protein gene promoters. 
24. The non-human mammal according to claim 20, 
wherein said mammal is female. 
25. The non-human mammal according to claim 20, 
wherein said mammal is male. 
26. The method according to claim 20, wherein said first, 
second, and third DNA segments further comprises an intron. 
27. The method according to claim 20, wherein said 
fibrinogen is human fibrinogen. 
28. A process for producing a transgenic non-human mam 
mal comprising: 
providing a first DNA segment encoding a first DNA 
encoding a heterologous fibrinogen AC chain, a second 
DNA segment encoding a second DNA encoding a het 
erologous fibrinogen Bf3 chain, and a third DNA seg 
ment encoding a third DNA encoding a heterologous 
fibrinogen Gy chain, wherein each chain is derived from 
the same species, and wherein each of said first, second 
and third segments is operably linked to a promoter 
containing regulatory sequence required for its expres 
sion in a mammary gland of a host female mammal; 
introducing said DNA segments into a fertilized egg of a 
non-human species heterologous to the species of origin 
of said fibrinogen chains; 
inserting said fertilized egg into an Oviduct or uterus of a 
female of said mammalian species; and 
allowing said fertilized egg to develop thereby producing a 
transgenic non-human mammal whose genome com 
prises said first, second and third DNA segments, which 
are expressed as individual AC, Bf3 and GY polypeptides 
that are assembled into biologically active fibrinogen in 
the cells of the mammary gland followed by the secre 
tion of the biologically active fibrinogen into the milk, if 
said mammal is a female progeny, resulting in the pro 
duction of recoverable quantities of biologically active 
fibrinogen from milk of said female progeny in concen 
trations of 30 g/ml or greater. 
29. The process according to claim 28, wherein said mam 
mal is female. 
30. The process according to claim 28, wherein said mam 
mal is male. 
